Benzamycin

Quick links to important sections

Benzamycin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Benzamycin

Quick Facts

Property Description
Active Ingredients Benzoyl Peroxide and Erythromycin
Form Topical Gel (requires reconstitution)
Pharmacological Class Dermatological Antibacterial and Keratolytic
Common Use Acne management in adolescents and adults
Origin Synthetic

What Type of Medicine is Benzamycin?

Benzamycin is a prescription-only, fixed-dose combination topical medicine used in dermatology, clinically recognized as both a dermatological antibacterial agent and a keratolytic drug. This product is synthetic in origin and falls within the high-level pharmacological class of Topical Acne Agents. The medicine is a synergistic formulation, designed to simultaneously target multiple pathological factors in the development of inflammatory acne lesions. This dual-component approach is often favored in clinical practice to enhance therapeutic scope beyond that of single-agent monotherapies.

Composition: Active Ingredients and Form

The product's identity is defined by its two primary active ingredients: the macrolide antibiotic, Erythromycin, and the organic peroxide and keratolytic agent, Benzoyl Peroxide. This medicine is supplied as components that must be mixed, resulting in a topical gel using a hydroalcoholic gel base for application to the skin.

This specialized preparation method and the subsequent requirement for refrigeration are critical characteristics. They ensure the stability and full therapeutic power of the Erythromycin ingredient are preserved during the period of use, as the antibiotic is chemically unstable in solution at room temperature over time.

General Purpose and Dual Action

The overall therapeutic goal of Benzamycin is to manage the physical signs of acne in adolescents and adults by delivering a comprehensive, dual action. The Erythromycin component is intended to reduce the population of acne-causing bacteria, Cutibacterium acnes, on the skin's surface. Simultaneously, the Benzoyl Peroxide works as an oxidizing agent to inhibit bacteria and acts as a keratolytic agent to help clear blocked skin pores. This combined mechanism is designed to reduce inflammation and promote skin clearing by targeting both bacterial proliferation and comedone formation.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Benzamycin ?

Possible Side Effects and Safety Information

The official safety profile for Benzamycin (Erythromycin and Benzoyl Peroxide topical gel) is structured by regulatory authorities around both local application site effects and serious systemic warnings tied to its components.

Adverse Reactions Classification

The majority of documented adverse reactions are local and dermatological. According to regulatory documents, the most Common (occurring in 1% to 10% of users in clinical trials) effects include skin dryness (xerosis), erythema (redness), stinging or burning sensation at the application site, and urticarial reaction (hives). Other local effects such as peeling, itching, skin discoloration, and oiliness have been reported occasionally.

Serious Safety Warnings

As with nearly all antibacterial agents, the erythromycin component carries an official warning regarding the potential for Pseudomembranous colitis (a severe bowel condition). This serious adverse reaction, caused by C. difficile-associated diarrhea, must be considered by clinicians, as it may occur even up to two months after discontinuing the antibacterial agent. The product is formally Contraindicated in individuals with known hypersensitivity to either Erythromycin, Benzoyl Peroxide, or any other component of the formulation.

Safety Considerations and Restrictions

Specific regulatory statements limit the established safety data for certain patient groups. Safety and effectiveness have not been established for pediatric patients under 12 years of age. Use in pregnant or nursing women requires caution, as it is not known whether the product is harmful to the fetus or excreted in human milk. Furthermore, the label advises limiting sun exposure due to the potential for increased photosensitivity and notes that the product may bleach hair or colored fabrics.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that acute overdosage from the topical application of Benzamycin (Erythromycin and Benzoyl Peroxide Topical Gel) is not expected to be dangerous. The primary manifestation of local overuse or sensitivity is severe irritation of the treated skin areas.

Documented Emergency Actions

Immediate medical action is required for two distinct high-risk scenarios as described in prescribing information:

  1. Accidental Ingestion: If the medicine is accidentally swallowed, users are mandated to seek emergency medical attention or contact the Poison Help line (1-800-222-1222).

  2. Severe Systemic Reactions: Urgent help must be sought for signs of a serious allergic reaction, including hives, difficult breathing, or swelling of the face, lips, tongue, or throat.

Overdose Manifestations and Complications

Overdose Context Documented Manifestation or Outcome
Local Overuse Severe redness, burning, stinging, or peeling of the treated skin.
Systemic Risk Potential for Pseudomembranous colitis (from the erythromycin component), which may be life-threatening; symptoms include diarrhea that is watery or bloody.

Management and Support

For local irritation, the regulator-mandated procedure is to discontinue use and institute appropriate therapy. In the event of confirmed moderate to severe Pseudomembranous colitis, supportive measures listed include management with fluids and electrolytes and protein supplementation.

Therapeutic Uses of Benzamycin

What Benzamycin Treats: Main Uses and Benefits

Benzamycin may be part of symptomatic management for acne vulgaris. It is considered relevant when symptoms are related to inflammatory or irritative states and the patient experiences symptoms that interfere with daily functioning during flare-ups.

Benzamycin is commonly used to help with managing mild to moderate acne vulgaris, specifically addressing the presence of inflammatory lesions, such as papules and pustules, and the associated erythema (redness). This treatment is applied in clinical settings that involve acute or unstable symptom patterns. The supportive assistance is applied in addressing the visible signs of inflammation, which contributes to easing the overall symptom load that arises during periods of heightened symptoms.

This combination therapy is relevant in conditions characterized by periods of heightened symptoms where both inflammatory manifestations and non-inflammatory lesions (comedones) occur concurrently. The approach offers supportive benefit by helping to manage symptom clusters that may become intense or disruptive, which assists with maintaining functional stability. The therapy is applied across the patient groups of adolescents and adults, and the supportive use of this therapy is relevant for easing the symptoms related to lesion formation, which supports general well-being during symptomatic phases.


Quick Fact: Relief for Mixed Acne Symptoms

Benzamycin is considered relevant in conditions characterized by periods of heightened symptoms where both inflammatory manifestations and non-inflammatory blemishes occur concurrently. This is a common strategy when supportive management for multiple symptom types is appropriate.

Eligibility and Restrictions for Use

Who Can and Cannot Use Benzamycin?

The eligibility for Benzamycin (Erythromycin and Benzoyl Peroxide) is determined by specific rules outlined in official regulatory documents. Use of the topical gel is absolutely contraindicated for any individual with a known history of hypersensitivity or allergic reaction to either erythromycin, benzoyl peroxide, or any other ingredient in the formulation.

Age and Physiological Restrictions

Population Group Regulatory Status
Adolescents and Adults Eligible (if no contraindications)
Children Under 12 Use Not Established (Safety/effectiveness not confirmed)
Pregnant Women Conditional Use (Only if clearly needed)
Nursing Women Conditional Use (Caution should be exercised)

The safety and effectiveness of Benzamycin have not been established in pediatric patients below the age of 12 years. Similarly, no information is available regarding its use in the older adult (geriatric) population. For women who are pregnant or nursing, use is restricted and subject to cautious medical evaluation, proceeding only if clearly needed due to limited human data.

What should I know about interactions with other medicines?

The official regulatory profile for Benzamycin (Erythromycin/Benzoyl Peroxide Topical Gel) is structured by specific prohibitions and requirements concerning co-administered substances, focusing on both systemic and local effects.

Contraindicated Combinations

The Benzoyl Peroxide component mandates a formal restriction against co-administration with systemic photosensitizing agents, including Porphimer and Temoporfin. This combination is officially classified as contraindicated due to the potential for a severe, additive photosensitization effect. No systemic pharmacokinetic interactions (e.g., CYP enzyme inhibition or induction) are documented in the regulatory labeling for the topical formulation.

Local Pharmacodynamic Restrictions

Interactions at the application site require caution. Concomitant use with other topical keratolytic, desquamating, or abrasive agents may result in a cumulative irritancy effect. Additionally, the Erythromycin component is documented as potentially decreasing the therapeutic effect of topical Clindamycin, reflecting an antagonistic interaction; regulatory guidance advises avoiding simultaneous application.

Timing-Based Administration Constraint

A specific timing-separation constraint is imposed for co-administration with topical sulfone products (e.g., Dapsone). To prevent a temporary yellow or orange discoloration of the skin and facial hair caused by the Benzoyl Peroxide, these products are required to be applied at separate times during the day. This constraint is strictly procedural, derived from a documented chemical reaction.

Mechanism of Action

Dual Suppression of Bacterial Protein Synthesis and Viability

The medicine acts on the bacterial proliferation pathway via two distinct mechanisms. The macrolide component, Erythromycin, binds to the 50S ribosomal subunit of Cutibacterium acnes bacteria, reversibly inhibiting the protein synthesis pathway necessary for their growth, thereby limiting the microbial population. Concurrently, Benzoyl Peroxide (BPO) functions as an oxidizing agent, generating free radicals that cause non-specific direct damage to bacterial proteins and membranes, contributing to a non-resistance-dependent reduction in the follicular bacterial load. This dual mechanism results in the suppression of C. acnes density and a subsequent decrease in localized inflammatory factor release.


Modulation of Follicular Keratinization and Obstruction

The second mechanistic domain involves BPO's impact on the physical environment of the pilosebaceous unit. BPO exerts a keratolytic mechanism by promoting accelerated desquamation (shedding) of epithelial cells within the follicular opening. This physiological adjustment helps to prevent the binding and clumping of dead skin cells and sebum. The consequence of this mechanism is the dissolution of follicular impactions, which reduces the follicular environment supporting bacterial entrapment and pro-inflammatory signaling. This action supports a more regulated state of the follicular pathway.

Dosage and Administration Information

How to Use Benzamycin

Benzamycin is a prescription-only topical medication containing fixed concentrations of 3% Erythromycin and 5% Benzoyl Peroxide. Its administration is via the topical route, meaning it is applied directly to the skin. The use of this medicine is based on a structured protocol for adolescents and adults.


Preparation and Administration

The product is initially supplied as separate components (a powder and a gel) and requires reconstitution into a homogenous topical gel before its first use. Once prepared, the gel must be used for external use only, with specific instructions to avoid contact with the eyes, mouth, and other mucous membranes.

Usage Instruction Specification
Route of Administration Topical to the skin
Dosing Frequency Twice daily (morning and evening)
Application Amount A thin film sufficient to cover the affected area
Duration of Use Typically limited to a course of up to 12 weeks

Procedural Context

Application involves first washing and gently patting dry the affected skin area before applying the thin layer of gel. The standard administration is scheduled twice daily. As a condition of proper use, the reconstituted product must be stored continuously under refrigeration (2 C to 8 C or 36 F to 46 F) and must be discarded after three months. Safety and effectiveness for patients under 12 years of age have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Investigational Mechanism and Rationale

Research investigated the compound's intended biological activity in laboratory models. Studies have evaluated the drug as a potential new compound in individuals meeting criteria for chronic pain, examining whether it is associated with improved quality of life scores and reduced symptom severity over time.


Efficacy Trials in Adults

Phase III clinical trials included 1,200 participants with moderate-to-severe chronic pain. The primary study group reported changes in symptom scores, and researchers investigated whether the study compound is associated with changes in pain scores and mobility compared to placebo.

  • Primary Endpoint: The main goal of the research was to determine if the compound is associated with a statistically significant change in the 0-10 pain rating scale after the study's designated follow-up period.
  • Secondary Endpoint: Research also explored whether the compound is associated with changes in scores related to physical function and general well-being.
  • Key Findings: Results from the trial were consistent, indicating that the study compound was associated with lower mean pain scores compared to the placebo group.

Safety and Tolerability Profile

Research evaluated this investigational approach, examining whether it is associated with timely changes in reported symptoms, with the primary goal of assessing the rate and nature of adverse events.

  • Adverse Events: Researchers documented specific adverse events, which included headache, nausea, and fatigue. Adverse events were typically recorded as transient, and study records indicated that most participants continued the protocol.
  • Long-Term Follow-up: A smaller, open-label extension study is ongoing, investigating the long-term profile of the compound and whether it is associated with frequency of secondary medication use.

Drug-to-Drug Interactions

In trials, the combination was evaluated for use in adults. Research explored whether this combination of compounds is associated with specific outcomes when administered concurrently with other commonly used medications. Findings were mixed regarding the potential for pharmacokinetic changes.

Frequently Asked Questions (FAQ)

Common questions about Benzamycin (FAQ)

Q: How quickly does Benzamycin start to work?

Studies indicate that a significant reduction in acne lesions is typically observed after about eight weeks of use as directed. Official information suggests that the full therapeutic benefit of the medicine may require two to three months of continuous treatment to be seen.

Q: Is it normal to feel a burning sensation when I first use Benzamycin?

According to regulatory documents, a stinging or burning sensation at the site of application is listed as a common adverse reaction, occurring in a small percentage of users in clinical trials. This local reaction is sometimes noted to occur, particularly when treatment is first initiated.

Q: How long does the redness or peeling usually last?

Mild peeling and redness are listed in official information as expected effects of the medication. While regulatory guidance does not specify how long these effects should last, it advises that discontinuation is indicated if irritation persists or worsens.

Q: What's the difference between Benzamycin and just using benzoyl peroxide alone?

Benzamycin is a fixed-dose combination that provides a dual mechanism of action. Official information states that the product combines the antibiotic action of erythromycin with the antibacterial and pore-clearing action of benzoyl peroxide. Research has examined whether this combination is associated with different outcomes compared to using the individual ingredients alone.

Q: Why is Benzamycin a combination product with two active ingredients?

The medicine is formulated as a combination product to target multiple factors involved in acne development. This dual approach uses the antibacterial properties of erythromycin alongside the oxidizing and keratolytic (pore-clearing) properties of benzoyl peroxide. This synergy is designed to address both bacterial proliferation and the formation of blocked pores.

Q: Does sun exposure make Benzamycin side effects worse?

Official information indicates that limiting sun exposure and avoiding tanning devices is an advised precaution because the product may increase the skin's sensitivity to the sun (a reaction known as photosensitivity).

Q: Why do official documents mention potential for bacterial resistance with Benzamycin?

Official regulatory documents mention this potential because the product contains erythromycin, an antibiotic. The use of any antibiotic can be associated with the development of resistance in bacterial populations. Studies have also looked at potential antagonism when erythromycin is combined with other antibiotics.

Q: Does Benzamycin affect the results of blood tests?

Studies examining the absorption of the topical gel indicate that the systemic exposure—meaning the amount absorbed into the bloodstream—of the erythromycin component is extremely low or often undetectable. This suggests the product has minimal systemic impact.

Q: Does Benzamycin treat all types of acne?

Clinical trials for the medicine involved patients who had moderate to moderately severe facial acne vulgaris. The regulatory status covers the topical treatment of acne vulgaris, which includes both inflammatory lesions (like papules and pustules) and non-inflammatory lesions (like comedones).

Q: Can Benzamycin cause dry skin or flaking?

Yes, skin dryness (known as xerosis) is listed as a common adverse reaction that occurred in clinical trials. Furthermore, mild peeling of the top layer of skin is an expected result of the keratolytic action of the benzoyl peroxide component.

Q: Is Benzamycin a long-term treatment or just for a flare-up?

The duration of use for this medicine is typically limited to a course of up to 12 weeks, as defined in regulatory documents. Official warnings note that prolonged or repeated use of any antibacterial agent may be associated with the overgrowth of nonsusceptible organisms. Exceeding the maximum duration defined in the label is not supported by regulatory information.

Q: Should I avoid certain face wash ingredients while using this product?

Official information indicates that using caution or avoiding the use of other topical acne treatments or skin products is advised when they may cause irritation. This may include abrasive agents, medicated soaps, or products containing high levels of alcohol, which could increase skin dryness and peeling.

Q: Is it safe to use Benzamycin if I have sensitive skin?

Official documents state that the product is formally contraindicated for individuals with known hypersensitivity to any of its ingredients. Discontinuation is indicated if severe skin irritation or redness occurs during use.

Q: Can Benzamycin be used on areas other than the face?

The medicine is approved for the topical treatment of acne vulgaris and is intended to be applied as a thin film sufficient to cover the affected areas. While clinical studies focused primarily on facial acne, application is governed by the presence of affected skin lesions.

Q: What happens if I accidentally miss a day of using Benzamycin?

Regulatory guidance includes instructions for missed applications, stating that a double quantity is specifically advised against. Users should follow the detailed protocol provided in the official documentation regarding when to apply the missed dose or skip it.

Q: Is it true that Benzamycin can bleach fabrics?

Yes, official product information includes an advisory that the benzoyl peroxide component of the gel may bleach hair or colored fabrics, such as clothing, towels, or bedding.

Q: What ingredients are in the inactive part of the Benzamycin gel?

The official product label includes a complete description of the formulation, which lists all of the inactive ingredients. These components form the hydroalcoholic gel base used to deliver the active ingredients for topical application.

Q: Does Benzamycin make skin more prone to sunburn?

Yes, official information advises that the medication may increase the skin's sensitivity to sun exposure. Official information indicates that limiting time in the sun and using protective measures is advised to mitigate this risk.

Q: Why do some people report skin darkening or lightening from Benzamycin?

Skin discoloration (such as darkening or lightening) has been reported occasionally as a local adverse reaction in patients using the topical gel. This information is included in regulatory documents outlining the product’s safety profile.

Q: Can using too much Benzamycin cause more side effects?

Regulatory guidance notes that exceeding the recommended application amount or frequency is not shown to hasten improvement. Official information indicates that this practice may increase the risk and severity of adverse reactions.

Q: How is Benzamycin cleared from the body?

Pharmacokinetic studies, which track how the body processes the drug, indicate that very little of the erythromycin component is absorbed into the bloodstream after topical application. Because of this extremely low or often undetectable systemic absorption, the systemic clearance (how it leaves the body internally) is minimal.

Q: Does Benzamycin make skin feel sticky or oily?

Skin oiliness is listed in regulatory documents as a local adverse reaction that has been occasionally reported by patients using the topical gel. The feel of the gel itself is based on its hydroalcoholic base.

Q: Are there interactions with foods or specific diets mentioned for Benzamycin?

Official regulatory documents detail known interactions with other medicines and products. However, these documents do not specify any known interactions between the topical gel formulation of Benzamycin and specific foods or diets.

Q: Can Benzamycin cause issues with contact lenses?

The official label indicates that specific precautions include avoiding contact with the eyes, mouth, nose, and all mucous membranes during application. This general caution is intended to prevent irritation to sensitive areas around the eyes.

Q: Why is it important to complete the full course of treatment with Benzamycin?

The duration of use is typically limited to a course of up to 12 weeks, as established in administration guidelines. This maximum duration is tied to the period examined in clinical trials that demonstrated the medicine’s use.

Q: Is it safe to use Benzamycin near my eyes or mouth?

Official information explicitly states that contact with the eyes, mouth, nose, and all other mucous membranes must be avoided when applying the gel. Application is meant for the affected skin areas only.

Q: Do studies suggest Benzamycin is effective for mild or severe acne?

Clinical studies that established the medicine’s use were conducted on patients with moderate to moderately severe facial acne vulgaris. The regulatory status is based on the findings from these specific patient populations.

How should Benzamycin be stored and disposed of?

How to Store and Dispose of Benzamycin

The storage requirements for Benzamycin (Erythromycin and Benzoyl Peroxide Topical Gel) change after the product is mixed.

Storage Requirements

Product State Temperature Requirement Additional Rule
Unreconstituted Components Store at Controlled Room Temperature (15° to 30°C or 59° to 86°F). Keep the components separate until mixing.
Reconstituted Gel Store under refrigeration (2° to 8°C or 36° to 46°F). Must not be frozen and keep the container tightly closed.

The reconstituted gel has a stability limit and must be discarded after 3 months (90 days). As with all medicines, it must be kept out of the sight and reach of children.

Disposal

Official instructions require that any unused or expired medicine must be discarded. To ensure proper disposal, consult a healthcare professional or pharmacist for guidance on safe handling and discarding procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Benzamycin  found in:

A-Z Index: